Search - tctmd.com

Displaying 421 - 440 of 480

Sort: Relevancy | Date

Presentation

Use and Associated Risks of Concomitant Aspirin with Oral Anticoagulation in A-fib Patients

Presenter: B. A. Steinberg

July 24, 2013

Presentation

RE-LY: Dabigatran vs. Warfarin and Hemorrhagic Stroke in Asians and Non-Asians with A-fib

Presenter: M. Hori

June 21, 2013

Presentation

Risks and Benefits of Anticoagulation in Atrial Fibrillation

Presenter: MW Cullen

June 20, 2013

Presentation TVT 2013

EP Perspective: Where Will A-fib Ablation Take Us in the Next Five Years?

Presenter: Darryl Wells

June 15, 2013

Presentation TVT 2013

Defining Nonvalvular A-fib: Not So Simple

Presenter: Michael Ezekowitz

June 15, 2013

Presentation TVT 2013

"New" Anticoagulation Options for A-fib: Beyond Warfarin

Presenter: Michael Ezekowitz

June 15, 2013

Presentation TVT 2013

Predictors of TAVR: Associated Strokes: New Onset Atrial Fibrillation, Postdilatation, and Others

Presenter: Josep Rodes-Cabau

June 12, 2013

Presentation

Oral Anticoagulation (OAC) and Antiplatelets inA-fib Patients After MI and PCI

Presenter: M. Lamberts

June 12, 2013

Presentation

Efficacy and Safety of Rivaroxaban in Patients with Heart Failure and Nonvalvular A-Efficacy and Safety of Rivaroxaban in Patients with Heart Failure and Nonvalvular A-fibfib

Presenter: Sean van Diepen

June 10, 2013

Presentation

Percutaneous LAA Closure with the Amplatzer Cardiac Plug in Patients with Nonvalvular A-fib and Contraindications for Anticoagulation Therapy

Presenter: M. Urena

May 28, 2013

Presentation

PROTECT AF: The Mortality Effects of LAA Closure vs. Warfarin for Stroke Prophylaxis in A-fib

Presenter: Vivek Y. Reddy

May 14, 2013

Presentation

Outcomes of Apixaban vs. Warfarin by Type and Duration of A-Fib; Results from the ARISTOTLE Trial

Presenter: Sana M. Al-Khatib

May 06, 2013

Presentation Fellows 2013

LAA Closure for Nonvalvular Atrial Fibrillation

Presenter: Mark Reisman

April 17, 2013

Presentation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: A.R. Harrington

April 05, 2013

Presentation ECHO 2013

Advanced TEE: Clinical Decision Making in Cryptogenic Stroke and Atrial Fibrillation

Presenter: Marco R. Di Tullio

April 04, 2013

Presentation

Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in ‘Real-World’ Patients with A-Fib

Presenter: T.B. Larsen

March 29, 2013

Presentation

Betrixaban vs. Warfarin in A-fib Patients: Results of a Phase 2, Randomized, Dose-Ranging Study

Presenter: Stuart J. Connolly

March 28, 2013

Presentation ACC 2013

Randomized Trial of LAA Closure vs Warfarin for Stroke/ Thromboembolic Prevention in Patients with Non-valvular Atrial Fibrillation (PREVAIL)

Presenter: David R. Holmes, Jr.

March 08, 2013

Presentation

Quality-of-Life Assessment in the Randomized PROTECT AF Trial of Patients at Risk for Stroke with Nonvalvular A-fib

Presenter: 147572|Oluseun Alli

February 27, 2013

Presentation

A-fib and Aortic Stenosis: Impact on Clinical Outcomes Among Patients Undergoing TAVR

Presenter: S. Stortecky

February 10, 2013

Advertisement

Use and Associated Risks of Concomitant Aspirin with Oral Anticoagulation in A-fib Patients

RE-LY: Dabigatran vs. Warfarin and Hemorrhagic Stroke in Asians and Non-Asians with A-fib

Risks and Benefits of Anticoagulation in Atrial Fibrillation

EP Perspective: Where Will A-fib Ablation Take Us in the Next Five Years?

Defining Nonvalvular A-fib: Not So Simple

"New" Anticoagulation Options for A-fib: Beyond Warfarin

Predictors of TAVR: Associated Strokes: New Onset Atrial Fibrillation, Postdilatation, and Others

Oral Anticoagulation (OAC) and Antiplatelets inA-fib Patients After MI and PCI

Efficacy and Safety of Rivaroxaban in Patients with Heart Failure and Nonvalvular A-Efficacy and Safety of Rivaroxaban in Patients with Heart Failure and Nonvalvular A-fibfib

Percutaneous LAA Closure with the Amplatzer Cardiac Plug in Patients with Nonvalvular A-fib and Contraindications for Anticoagulation Therapy

PROTECT AF: The Mortality Effects of LAA Closure vs. Warfarin for Stroke Prophylaxis in A-fib

Outcomes of Apixaban vs. Warfarin by Type and Duration of A-Fib; Results from the ARISTOTLE Trial

LAA Closure for Nonvalvular Atrial Fibrillation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Advanced TEE: Clinical Decision Making in Cryptogenic Stroke and Atrial Fibrillation

Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in ‘Real-World’ Patients with A-Fib

Betrixaban vs. Warfarin in A-fib Patients: Results of a Phase 2, Randomized, Dose-Ranging Study

Randomized Trial of LAA Closure vs Warfarin for Stroke/ Thromboembolic Prevention in Patients with Non-valvular Atrial Fibrillation (PREVAIL)

Quality-of-Life Assessment in the Randomized PROTECT AF Trial of Patients at Risk for Stroke with Nonvalvular A-fib

A-fib and Aortic Stenosis: Impact on Clinical Outcomes Among Patients Undergoing TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content